A woolly debate: the rights and wrongs of cloning

“Should life be patented?” asks Paul Chapman, head of Avidity’s life sciences team, relaying the concern of the UK public and intellectual property officials when the creators of Dolly the Sheep sought to patent their experiment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

Biotech

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

20 July 2026 The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.

Biotech

Illumina ordered to recall products after German patent ruling

16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.

More features

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UK Prime Minister axes science ministry in govt shakeup

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Why is 2026 already a record year for M&A activity?

A woolly debate: the rights and wrongs of cloning

More on this story

Editor's picks

Editor's picks

More features